Market Research Reports

  BIS healthcare experts have found the pharmacogenomics services industry to be one of the most rapidly evolving and dynamic markets. The global  pharmacogenomics services market  is projected to reach $9,346.8 million by 2031 from $5,060.0 million in 2020, at a CAGR of 5.71% during the forecast period 2021-2031. The market is driven by certain factors, including increasing prevalence of infectious diseases and various types of cancer, increasing adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug discovery and development. Currently, the pharmacogenomics services industry is witnessing an upsurge due to the increasing prevalence of infectious diseases and various types of cancer, increase in adoption of personalized medicine shifting the paradigm from reaction to prevention, increasing rate of adverse drug reaction, and surge in usage of pharmacogenomics for drug

  Capillary electrophoresis encompasses a rapidly evolving range of consumables, software, and systems that facilitate pathogen detection, viral load estimation, antibiotic and antiviral therapy selection, diagnosis of cancer, and other diseases, by the detection and analysis of proteins and nucleic acid sequences. Capillary electrophoresis also offers prognostic assessments for a wide range of diseases, as well as assistance with treatment selection and monitoring of drug treatment efficacy and is broadly used for nucleic acid analysis and protein analysis applications. Our healthcare experts have found the   Capillary electrophoresis market  to be one of the stable markets, and the global market is predicted to grow at a CAGR of 5.66% during the forecast period 2021-2031. Factors fueling the growth of the market include strategic initiatives by key market players and increasing adoption of sequencing in various research fields increase in adoption of personalized medicine; despite ra

  The global neoantigen cancer vaccine industry analysis by BIS Research projects the market to grow at a significant CAGR of 77.73% during the forecast period 2024-2031. The  neoantigen cancer vaccine market  is expected to generate $35.5 million in revenue in 2024, owing to the expected launch of the first neoantigen vaccine, DC vaccine in the market. The neoantigen cancer vaccine market growth has been primarily attributed to major drivers in this market, such as rising prevalence of cancers, increasing adoption of personalized medicine to tailor patient’s treatment on an individual level, and significant external funding for executing research and development exercises. However, significant challenges are restraining the market growth. These challenges include the expected higher cost of personalized cancer vaccines, hurdles in clinical development, and payer uncertainty and outcome-based pricing. The global neoantigen cancer vaccine market has been analyzed on the basis of segment

  Dental radiographic procedures are employed to assess overall oral health and detect anatomical deformities arising due to congenital defects, developmental disorders, and acquired traumatic injuries. The dental disorders occurring in the patients, including dental caries, periodontal diseases, tooth erosion, cracked tooth, cleft palate, cyst, tumorous growth, and abscess, can be diagnosed through dental radiographic procedures. The global dental radiography market is projected to witness significant growth during the forecast period 2022-2031. The high prevalence and growing incidences of oral cancer, oral disorders and the technological advancements in dental radiography systems are the key propellers for the growth of the market. The development of advancements such as integration of software with the dental imaging systems, arises in dental tourism and increased awareness regarding dental care and oral hygiene are leading to the evolving of dental radiography continuously. In ter